Agitation in Patients With Dementia of the Alzheimer's Type

Neurology
5
Pipeline Programs
1
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
4
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Axsome Therapeutics
Axsome TherapeuticsNY - New York
5 programs
1
4
AXS-05Phase 31 trial
AXS-05Phase 31 trial
AXS-05Phase 31 trial
AXS-05Phase 31 trial
AXS-05Phase 2/31 trial
Active Trials
NCT03226522Completed366Est. Apr 2020
NCT04797715Completed178Est. Nov 2022
NCT06736509Terminated139Est. Apr 2025
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Axsome TherapeuticsAXS-05
Axsome TherapeuticsAXS-05
Axsome TherapeuticsAXS-05
Axsome TherapeuticsAXS-05
Axsome TherapeuticsAXS-05

Clinical Trials (5)

Total enrollment: 1,547 patients across 5 trials

NCT06736509Axsome TherapeuticsAXS-05

An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study

Start: Nov 2024Est. completion: Apr 2025139 patients
Phase 3Terminated
NCT05557409Axsome TherapeuticsAXS-05

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation

Start: Sep 2022Est. completion: Dec 2024408 patients
Phase 3Completed
NCT04947553Axsome TherapeuticsAXS-05

A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation

Start: Jun 2021Est. completion: Dec 2024456 patients
Phase 3Completed
NCT04797715Axsome TherapeuticsAXS-05

Assessing Clinical Outcomes in Alzheimer's Disease Agitation

Start: Dec 2020Est. completion: Nov 2022178 patients
Phase 3Completed
NCT03226522Axsome TherapeuticsAXS-05

Addressing Dementia Via Agitation-Centered Evaluation

Start: Jul 2017Est. completion: Apr 2020366 patients
Phase 2/3Completed

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
8h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
8h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
9h ago

Director of Finance

CoMind
London, UK
9h ago

Electronics Engineering Manager

CoMind
London, UK
9h ago

Director of Information Technology

Zavation Medical Products
9h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)